Aussie Fluoroscence Firm Fluorotechnics Files IPO, Hopes to Raise Up to $9.7M | GenomeWeb
Upstart Australian proteomics firm Fluorotechnics last week filed for an initial public offering in the hopes of raising up to Aus$12 million ($9.7 million).
The company’s stock would be traded on the Australian Stock Exchange and has an issue price of Aus$1 per share. Fluorotechnics expects the IPO to float between 26 million 28 million shares and yield a market cap of between Aus$26 million and Aus$28 million.
BBY is the lead manager on the float.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.